Compare CDP & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDP | RARE |
|---|---|---|
| Founded | 1988 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.2B |
| IPO Year | N/A | 2014 |
| Metric | CDP | RARE |
|---|---|---|
| Price | $29.63 | $36.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | $33.29 | ★ $85.20 |
| AVG Volume (30 Days) | 882.8K | ★ 1.3M |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | ★ 9.45 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $752,757,000.00 | $630,598,000.00 |
| Revenue This Year | N/A | $19.09 |
| Revenue Next Year | $4.48 | $20.62 |
| P/E Ratio | $22.46 | ★ N/A |
| Revenue Growth | 0.43 | ★ 20.63 |
| 52 Week Low | $23.92 | $25.81 |
| 52 Week High | $33.49 | $50.00 |
| Indicator | CDP | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 63.79 |
| Support Level | $29.59 | $33.16 |
| Resistance Level | $30.99 | $34.77 |
| Average True Range (ATR) | 0.58 | 1.55 |
| MACD | -0.02 | 0.34 |
| Stochastic Oscillator | 46.85 | 88.32 |
COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.